15:00 – 15:15 – Welcome ceremony
Presidential session
15:15 – 15:45 – Progress in the Definition of Biomarkers for Immune Checkpoint Inhibitor Treatment – Prof. Dr. Christoph Zielinski
15:45 – 16:15 – Standards and future direction in RCC – Prof. Dr. Christoph Zielinski
16:15 – 16:45 – Molecular biology – mandatory tests – when, how, for whom? – Prof. Dr. Luka Brcic
16:45 – 17:15 – What is the place of radioligand therapy in prostate cancer – Prof. Dr. Gabriel Kacso
17:15 – 17:45 – Break
Screening and prophylaxis
17:45 – 18:15 – Electronic cigarettes – no harm? –Prof. Dr. Florin Mihaltan
18:15 – 18:45 – Lung cancer screening – facts, figures, and national perspectives –Conf. Dr. Laurentia Gales
18:45 – 19:00 – European Projects Presentation – INTERACT, TRANSITION, SOLACE
Diagnostic
19:00 – 19:30 – New Radiotracers for molecular imaging and targeted therapy in oncology –Conf. Univ. Dr. Mirela Gherghe
19:30 – 20:00 – AI – human – independent diagnostic tools? – Conf. Univ. Dr. Liviu Bilteanu
Lung cancer
15:00 – 15:30 – Oncogene driven – new molecular targets – how to address – Dr. Andrei Ungureanu
15:30 – 16:00 – Non-oncogene driven – early stages – Dr. Mircea Dediu
16:00 – 16:30 – Non-oncogene -driven metastatic – news in immunotherapy of metastatic lung cancer – Dr. Dana Clement
16:30 – 17:00 – News in the radiotherapy of the lung – Dr. Mihai Teodor Georgescu
17:00 – 17:20 – Satellite Symposium AstraZeneca – Standards of treatment in NSCLC and SCLC – Dr. Amedeia Niță
17:20 – 17:50 – Coffee Break
17:50 – 18:30 – Educational Session Novartis -Breast cancer: from early stages to aggressive disease – Conf. Dr. Laurentia Gales
18:30 – 19:00 – Satellite Symposium Eli Lilly – How is Verzenios different within the iCDK4/6 class? – Dr. Stefania Toma
19:00 – 19:20 – Satellite Symposium AstraZeneca – Extend HER2+ expectations – Prof. Dr. Rodica Anghel
Breast Cancer
19:20 – 19:50 – News from St. Galen and ASCO – Dr. Alexandru Eniu
19:50 – 20:20 – CDk4/6 and radiation therapy – Prof. Dr. Laura Rebegea
20:20 – 20:50 – Metastatic TNBC – optimal first line and subsequent treatments – Prof. Dr. Rupert Bartsch
20:50 – 21:20 – HER2 positive ABC – optimal first line and subsequent treatments – Prof. Dr. Rupert Bartsch
16:00 – 16:30 – Standards and limits in diagnostic and staging of MM
– Prof. Univ. Dr. Alexandru Blidaru, Conf.Dr. Silviu Voinea, Șef Lucr.Dr. Cristian Bordea
16:30 – 17:00 – Sarcoma: update 2023 – Prof. Dr. Thomas Brodowicz
17:00 – 17:30 – SatelliteSymposium–MSD–KEYNOTE048:Long-termexcellenceandclinicalpracticeinHNSCC–Conf.Univ.Dr.AncaZgura
17:30 – 17:45 – COFFEE BREAK
Urogenital cancer
17:45 – 18:15 – Satellite Symposium– ASTELLAS –What dowe need to knowabout enzalutamide inmCRPC and guidelines
recommendations – Conf. Dr. Oana Trifanescu
18:15 – 18:30 – Satellite Symposium Ipsen – Monotherapy in the treatment of RCC – Dr. Andreea Lăzescu
18:30 – 19:00 –What is New in Urothelial Tumors – Prof. Dr. Viorel Jinga, Dr. Cristian Sima
20:00 – 20:30 – New options for prostate cancer – mHSPC, nmCRPC, PARP inhibitors – Prof. Dr. Serban Negru
Treatment
19:30 – 20:00 – Radiotherapy of children and adolescents – unmet needs – Conf. Dr. Radu Mitrica
20:00 – 20:30 – Radio-immunotherapy – Prof. Dr. Rodica Anghel, Șef Lucrări Dr. Luiza Șerbănescu, Conf. Dr. Oana Trifănescu
Gastrointestinal cancers
15:30 – 16:00 – Liver metastases – the place of interventional radiology – Sef Lucrari Dr. Mugur Grasu
16:00 – 16:30 – Optimizing the Prognosis in Pretreated mCRC Patients: Novel Options – Prof. Dr. Gerald Prager
16:30 – 17:00 – ESMO clinical practice guidelines for metastatic colorectal cancer – Conf. Dr Michael Schenker
17:00 – 17:30 – Hepatobiliary cancers – advanced treatment options – Conf. Dr. Oana Trifanescu
17:30 – 17:50 – Satellite Symposium Servier – More time for moments that matter: management of metastatic colorectal and gastric cancer patients – Conf. Dr. Laurentia Gales
Genital cancers
17:50 – 18:20 – Ovarian cancer – Prof. Dr. Alexander Reinthaller
18:20 – 18:50 COFFEE BREAK
18:50 – 19:10 – Satellite Symposium AstraZeneca – Looking beyond BRCA mutations in ovarian cancer: HRD testing – Dr. Maria Olinca
19:10 – 19:40 – Cervical cancer – any changes after intensive prophylaxis and screening? – Prof. Dr. Patriciu Achimas-Cadariu